Data as of Jan 29
| +0.07 / +1.14%|
The 1 analysts offering 12-month price forecasts for Ocata Therapeutics Inc have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +156.82% increase from the last price of 6.23.
The current consensus among 1 polled investment analysts is to Buy stock in Ocata Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.